Rory McCrimmon trained at the University of Edinburgh and completed his clinical and speciality training in the South-East of Scotland before becoming an NHS Consultant Physician in Diabetes and Endocrinology at University Hospital Aintree, Liverpool, in 2000. In 2002, he joined the faculty at Yale University, Connecticut, to investigate why people with type 1 and 2 diabetes are very prone to developing low glucose (Hypoglycaemia). He returned to Scotland in 2009 to establish his laboratory at the University of Dundee, where he is currently Professor of Experimental Diabetes and Metabolism and Honorary Consultant, and to develop his clinical interests in Hypoglycaemia Unawareness and Exercise in Type 1 diabetes. He was recently awarded the 2015 RD Lawrence Lecture by Diabetes UK for his research in Hypoglycaemia. Prof McCrimmon is currently research lead for the Academic Health Sciences Partnership in Tayside. Serves on Editorial Boards of Diabetologia, Diabetes Care and the Journal of Endocrinology and Metabolism. He is a panel member for: Diabetes UK, Clinical Studies Group Management Committee; Diabetes UK, Intermediate Clinical Fellowships Panel; Juvenile Diabetes Research Foundation PEAK Programme; Panel member, International Hypoglycaemia Study Group; Panel Member Medical Research Council Clinical Fellowship Training and Career Development Awards panel; Panel Member, Research Advisory Board, Diabetes Research & Wellness Foundation.

McCrimmon RJ. Old habits are hard to break: Lessons from the study of hypoglycaemia. Diabetic Medicine (in press) Haythorne , E., Hamilton, D. L., Findlay, J. A., Beall, C., McCrimmon, RJ & Ashford, M. Chronic exposure to KATP channel openers results in attenuated glucose sensing in hypothalamic GT1-7 neurons. Neuropharmacology. 2016 111:212-222. George, PS, McCrimmon RJ. Saxagliptin co‐therapy in C‐peptide negative Type 1 diabetes does not improve counter‐regulatory responses to hypoglycaemia. Diabetic Medicine 2016. Vol. 33, No. 9, 28.12.2015, p. 1283-1290. Read SH, Kerssens JJ, McAllister DA, Colhoun HM, Fischbacher CM, Lindsay RS, McCrimmon RJ, McKnight JA, Petrie JR, Sattar N, Wild SH; Scottish Diabetes Research Network Epidemiology Group. Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetolgia 2016 Oct;59(10):2106-13. McNeilly AD, Gallagher JR, Dinkova-Kostova AT, Hayes JD, Sharkey J, Ashford MLJ, McCrimmon RJ. Nrf2-mediated neuroprotection against recurrent hypoglycemia is insufficient to prevent cognitive impairment in a rodent model of type 1 diabetes. Diabetes 2016 Oct;65(10):3151-60 Aucott LS, Philip S, Avenell A, Afolabi E, Sattar N, Wild S, Emslie Smith Fischbacher C, Cunningham S, Looker H, Colhoun H, Petrie J, McKnight J, Lindsay R, McCrimmon RJ, Leese G, Scottish Diabetes Research Network Epidemiology Group. BMJ Open e010836. Yavari, A., C. J. Stocker, S. Ghaffari, E. T. Wargent, V. Steeples, G. Czibik, K. Pinter, M. Bellahcene, A. Woods, P. B. Martinez de Morentin, C. Cansell, B. Y. Lam, A. Chuster, K. Petkevicius, M. S. Nguyen-Tu, A. Martinez-Sanchez, T. J. Pullen, P. L. Oliver, A. Stockenhuber, C. Nguyen, M. Lazdam, J. F. O'Dowd, P. Harikumar, M. Toth, C. Beall, T. Kyriakou, J. Parnis, D. Sarma, G. Katritsis, D. D. Wortmann, A. R. Harper, L. A. Brown, R. Willows, S. Gandra, V. Poncio, M. J. de Oliveira Figueiredo, N. R. Qi, S. N. Peirson, R. J. McCrimmon, B. Gereben, L. Tretter, C. Fekete, C. Redwood, G. S. Yeo, L. K. Heisler, G. A. Rutter, M. A. Smith, D. J. Withers, D. Carling, E. B. Sternick, J. R. Arch, M. A. Cawthorne, H. Watkins and H. Ashrafian "Chronic Activation of gamma2 AMPK Induces Obesity and Reduces beta Cell Function." Cell Metab 2016 23(5): 821-836. Wilkin T, Greene S, McCrimmon R. Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1). Diabetes Obes Metab. 2016 Jan;18(1):3-5. PubMed PMID: 26511442. McNeilly AD, McCrimmon RJ. The Scylla and Charybdis of glucose control in childhood type 1 diabetes? Pediatr Diabetes. 2015 Jun;16(4):235-41. PubMed PMID: 25727089. Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, et al. Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia. 2015 Apr;58(4):716-25. PubMed PMID: 25669630. Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015 Jan 6;313(1):37-44. PubMed PMID: 25562264. Pubmed Central PMCID: 4426486. George PS, Tavendale R, Palmer CN, McCrimmon RJ. Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes. Diabetes. 2015 Jun;64(6):2234-41. PubMed PMID: 25591873. Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, et al. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 2014 Sep;34(17):3305-20. PubMed PMID: 24958099. Pubmed Central PMCID: 4135558. McCrimmon RJ. The challenges of hypoglycemia in the community. Diabetic Hypoglycemia. 2014 1;6(3):1. McCrimmon RJ. Challenges associated with exercise in type 1 diabetes. Diabetic Hypoglycemia. 2014 6;7(1):1-2. McNay EC, Teske JA, Kotz CM, Dunn-Meynell A, Levin BE, McCrimmon RJ, et al. Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance. a model for weight gain with intensive insulin therapy. American Journal of Physiology 2013 1/15;304(2):E131-E8. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in Type 1 diabetes. Diabetic Medicine. 2013 2/1;30(2):179-88. George P, McCrimmon RJ. Avoiding hypoglycemia during protracted physical exercise by utilizing modern technology. Diabetic Hypoglycemia. 2013 2/28;5(3):12-4. Gardiner A, George PS, Pearson E, McCrimmon RJ. An interesting case of new-onset ketosis-prone diabetes in a Scottish teaching hospital. British Journal of Diabetes and Vascular Disease. 2013 10/1;13(5-6):265-8. Beall C, Watterson KR, McCrimmon RJ, Ashford MLJ. AMPK modulates glucose-sensing in insulin-secreting cells by altered phosphotransfer to KATP channels. Journal of Bioenergetics and Biomembranes. 2013 6;45(3):229-41. Beall C, Haythorne E, Fan X, Du Q, Jovanovic S, Sherwin R, et al. Continuous hypothalamic KATP channel activation blunts glucose counter-regulation in vivo in rats and supresses KATP conductance in vitro. Diabetologia. 2013 9;56(9):2088-92. Yang L, Isoda F, Yen K, Kleopoulos SP, Janssen W, Fan X, et al. Hypothalamic Fkbp51 is induced by fasting, and elevated hypothalamic expression promotes obese phenotypes. American Journal of Physiology, Endocrinology and Metabolism. 2012;302(8):E987-E91. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012 6/16;379(9833):2291-9. McCrimmon RJ, Oz G. Cerebral adaption to recurrent hypoglycemia. Translational Endocrinology and Metabolism. Chevy Chase, MD: Endocrine Society; 2012. p. 89-114. George P, McCrimmon RJ. Diazoxide. Practical Diabetes International. 2012 1/1;29(1):36-7.